Related Experiment Video
Updated: Jun 30, 2026
The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
Published on: August 2, 2017
FABP4 as an immunometabolic hub in preeclampsia: from maternal-fetal interface to systemic inflammation
1Medical Laboratory Department, Affiliated Dongtai Hospital of Nantong University, Dongtai, Jiangsu, China.
Insights
Fatty acid binding protein 4 (FABP4) is elevated in preeclampsia (PE), acting as an immunometabolic hub. Targeting FABP4 may offer new interventions for this pregnancy disorder.
Area of Science:
- Immunometabolism
- Reproductive Biology
- Vascular Biology
Background:
- Preeclampsia (PE) pathogenesis is shifting from placental ischemia to immunometabolic disorders.
- Fatty acid binding protein 4 (FABP4) is increasingly recognized for its role in metabolic and inflammatory processes.
Purpose of the Study:
- To propose a conceptual framework positioning FABP4 as a central immunometabolic hub in PE pathogenesis.
- To explore the spatiotemporal cascade linking FABP4 to local immune imbalance and systemic vascular injury in PE.
Main Methods:
- Review of clinical studies showing elevated FABP4 in PE.
- Extrapolation of intracellular lipotoxic pathways and their role in macrophage polarization and NLRP3 inflammasome activation.
- Analysis of studies on FABP4 inhibition in trophoblast-like cells and its extracellular effects on endothelial dysfunction.
Main Results:
- FABP4 is significantly upregulated in PE placentas and maternal circulation, partly due to epigenetic mechanisms.
- Intracellularly, FABP4 modulates macrophage polarization and activates the NLRP3 inflammasome, impacting trophoblast viability under metabolic stress.
- Extracellular FABP4 may drive systemic inflammation and endothelial dysfunction in PE.
Conclusions:
- FABP4 represents a critical immunometabolic hub in PE, linking placental dysfunction to systemic vascular injury.
- FABP4's role in macrophage polarization and trophoblast viability highlights its potential as a therapeutic target.
- Further research, including single-cell quantification, is needed to fully elucidate FABP4's role in specific placental subpopulations and its translational potential for PE intervention.
Abstract:
Preeclampsia (PE) is a multisystem vascular disease that occurs specifically during pregnancy, and the understanding of its pathogenesis is gradually shifting from the traditional "placental ischemia-endothelial injury" model to immunometabolic disorders. In this article, we propose a conceptual framework positioning fatty acid binding protein 4 (FABP4) as an immunometabolic hub in the pathogenesis of PE. Clinical studies suggest that FABP4 is significantly elevated in preeclamptic placentas and maternal circulation; epigenetic derepression via miR-148a/152-mediated DNMT1 downregulation contributes to this placental upregulation. Leveraging its primary identity as an intracellular lipid chaperone, we hypothesized a spatiotemporal cascade linking local immune imbalance to systemic vascular injury. Intracellularly, drawing upon highly conserved lipotoxic pathways established in non-pregnancy models, we extrapolate that FABP4 participates in the regulation of the immune microenvironment at the maternal-fetal interface by modulating macrophage polarization toward the M1-type and activating the NLRP3 inflammasome axis; a recent study in an EVT-derived cell line (HTR-8/SVneo) demonstrated that pharmacological inhibition or siRNA knockdown of FABP4 impairs mitochondrial membrane potential, reduces ATP synthesis, and increases oxidative stress, resulting in proliferative arrest. These findings position FABP4 as a viability factor for trophoblast-like cells under metabolic stress, though direct validation in primary EVTs is still required. Extracellularly, upon entering maternal circulation, FABP4 may trigger systemic inflammatory cascade responses and induce endothelial dysfunction. While single-cell transcriptomic studies have revealed significant reprogramming of lipid metabolism-related gene expression in PE placental immune cells, direct single-cell quantification of FABP4 across specific placental subpopulations remains to be performed. Consequently, by integrating macroscopic clinical data with these microscopic intercellular networks, we frame the FABP4-driven axis as a plausible mechanistic convergence, highlighting its promise as a critical translational target for immunometabolic intervention.
